Inhibitors of Civ1 kinase belonging to 6-aminoaromatic-2-cyclohexyldiamino purine series as potent anti-fungal compounds

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1697, Issue 1-2, 2004, Pages 211-223

  Bordon Pallier, Florence ^a   Jullian, Nathalie ^a   Ferrari, Paul ^a   Girard, Anne Marie ^a   Bocquel, Marie Thérèse ^a   Biton, Jacques ^a   Bouquin, Nicolas ^a   Haesslein, Jean Luc ^a  

^a SANOFI   (France)

Author keywords

A.; Antifungal agent; Aspergillus; C.; Ca; CAK; Cak1; Candida; Candida albicans; CDK; Civ1; CTD; Cyclin dependent kinase; Cyclin dependent kinase activating kinase activity; Drug screening; Purine derivative; Yeast cell cycle; Yeast protein kinase

Indexed keywords

6 AMINOAROMATIC 2 CYCLOHEXYLDIAMINOPURINE; 6 N (3,3 DIMETHYLALLYL)ADENINE; 6 N,N DIMETHYLADENINE; ADENINE; AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; FLUCYTOSINE; FUMAGILLIN; FUNGAL ENZYME; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MORPHOLINE DERIVATIVE; NAFTIFINE; NYSTATIN; OLOMOUCINE; POLYENE ANTIBIOTIC AGENT; PROTEIN KINASE; PROTEIN KINASE CIV1; PURINE DERIVATIVE; PYRROLE; ROSCOVITINE; TERBINAFINE; THIOCARBAMIC ACID DERIVATIVE; TOLNAFTATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIFUNGAL ACTIVITY; CELL CYCLE; CHILL; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEVER; GRAND MAL SEIZURE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SHOCK; VOMITING;

AMINO ACID SEQUENCE; ANTIFUNGAL AGENTS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FUNGAL PROTEINS; FUNGI; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN-SERINE-THREONINE KINASES; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; EUKARYOTA; FUNGI;

EID: 1542358847     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2003.11.025     Document Type: Conference Paper

References (113)

1. Rivitti E.A., Aoki V. Deep fungal infections in tropical countries. Clin. Dermatol. 17:1999;171-190.
2. Rios-Fabra A., Moreno A.R., Isturiz R.E. Fungal infection in Latin American countries. Infect. Dis. Clin. North Am. 8:1994;129-154.
3. Anaissie E., Bodey G.P. Nosocomial fungal infections. Old problems and new challenges. Infect. Dis. Clin. North Am. 3:1989;867-882.
4. McNeil M.M., Nash S.L., Hajjeh R.A., Phelan M.A., Conn L.A., Plikaytis B.D., Warnock D.W. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33:2001;641-647.
5. Dixon D.M., McNeil M.M., Cohen M.L., Gellin B.G., La Montagne J.R. Fungal infections: a growing threat. Public Health Rep. 111:1996;226-235.
6. Pfaller M.A., Diekema D.L., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., Messer S.A. the SENTRY participant group International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39:2001;3254-3259.
7. Pfaller M.A., Diekema D.L., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., Messer S.A. the SENTRY participant group Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40:2002;852-856.
8. Abi-Said D.E., Anaissie E., Uzun O., Raad I.I., Pinzcowski H., Vartivarian O. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1997;1122-1128.
9. Borg-von Zepelin M., Eiffert H., Kann M., Ruchel R. Changes in the spectrum of fungal isolates: results from clinical specimens gathered in 1987/ 88 compared with those in 1991/92 in the University Hospital Gottingen, Germany. Mycoses. 36:1993;247-253.
10. Costa S.F., Marinho I., Araujo E.A., Manrique A.E., Medeiros E.A., Levin A.S. Nosocomial fungaemia: a 2-year prospective study. J. Hosp. Infect. 45:2000;69-72.
11. D'Agata E.M., Mount D.B., Thayer V., Schaffner W. Hospital-acquired infections among chronic hemodialysis patients. Am. J. Kidney Dis. 35:2000;1083-1088.
12. Fernandez M., Moylett E.H., Noyola D.E., Baker C.J. Candidal meningitis in neonates: a 10-year review. Clin. Infect. Dis. 31:2000;458-463.
13. Hung C.C., Chen M.Y., Hsieh S.M., Sheng W.H., Chang S.C. Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study. J. Acquir. Immune Defic. Syndr. 24:2000;378-385.
14. Viscoli C., Girmenia C., Marinus A., Collette L., Martino P., Vandercam B., Doyen C., Lebeau B., Spence D., Kremery V., De Pawn B., Meunier F. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1999;1071-1079.
15. Bodey G.P., Mardini M., Hanna H.A., Boktour M., Abbas J., Girgawy E., Hachem R.Y., Kontoyiannis D.P., Raad I.I. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med. 112:2002;380-385.
16. Sullivan D., Haynes K., Bille J., Boerlin P., Rodero L., Lloyd S., Henman M., Coleman D. Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J. Clin. Microbiol. 35:1997;960-964.
17. Wingard J.R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis. 20:1995;115-125.
18. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 18:1991;1274-1277.
19. Moran G.P., Sullivan D.J., Coleman D.C. Emergence of non-Candida albicans Candida species as pathogens. Calderone R.A. Candida and Candidiasis. 2002;37-53 ASM Press, Washington, DC.
20. Fidel P.L., Vazquez J.A., Sobel J.D. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin. Microbiol. Rev. 12:1999;80-96.
21. Wenzel R.P. Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. 20:1995;1531-1534.
22. Redding S.W. The role of yeasts other than Candida albicans in oropharyngeal candidiasis. Curr. Opin. Infect. Dis. 14:2001;673-677.
23. Brookman J.L., Denning D.W. Molecular genetics in Aspergillus fumigatus. Curr. Opin. Microbiol. 3:2000;468-474.
24. Patterson T.F. Invasive mycoses: management and unmet medical needs. Curr. Opin. Infect. Dis. 14:2001;669-671.
25. Denning D.W. Invasive aspergillosis. Clin. Infect. Dis. 26:1998;781-805.
26. Lin S., Schranz J., Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32:2001;358-366.
27. Latge J.P. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:1999;310-350.
28. Latge J.P. The pathobiology of Aspergillus fumigatus. Trends Microbiol. 9:2001;382-389.
29. Pappas P.G., Perfect J.R., Cloud G.A., Larsen R.A., Pankey G.A., Lancaster D.J., Henderson H., Kauffman C.A., Haas D.W., Saccente M., Hamill R.J., Holloway M.S., Warren R.M., Dismukes W.E. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 33:2001;690-699.
30. Galgiani J.N., Ampel N.M., Catanzaro A., Johnson R.H., Stevens D.A., Williams P.L. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin. Infect. Dis. 30:2000;658-661.
31. Pondrom J., Lee P., Stark P. Diagnostic case study: radiographic findings in pulmonary blastomycosis. Semin. Respir. Infect. 15:2000;336-338.
32. Pound M.W., Drew R.H., Perfect J.R. Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. Curr. Opin. Infect. Dis. 15:2002;183-194.
33. Silveira F., Nucci M. Emergence of black moulds in fungal disease: epidemiology and therapy. Curr. Opin. Infect. Dis. 14:2001;679-684.
34. Sanglard D., Bille J. Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections. Calderone R.A. Candida and Candidiasis. 2002;355-383 ASM Press, Washington, DC.
35. Neely M.N., Ghannoum M.A. The exciting future of antifungal therapy. Eur. J. Clin. Microbiol. Infect. Dis. 19:2000;897-914.
36. Hossain M.A., Ghannoum M.A. New investigational antifungal agents for treating invasive fungal infections. Expert Opin. Investig. Drugs. 9:2000;1797-1813.
37. Hossain M.A., Ghannoum M.A. New developments in chemotherapy for non-invasive fungal infections. Expert Opin. Investig. Drugs. 10:2001;1501-1511.
38. Gupte M., Kulkarni P., Ganguli B.N. Antifungal antibiotics. Appl. Microbiol. Biotechnol. 58:2002;46-57.
39. Groll A.H., Piscitelli S.C., Walsh T.J. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44:1998;343-500.
40. Burt E.T. Current approaches to the treatment of Candida albicans infections. Expert Opin. Ther. Pat. 11:2001;269-282.
41. Tkacz J.S., DiDomenico B. Antifungals: what's in the pipeline. Curr. Opin. Microbiol. 4:2001;540-545.
42. Arathoon E.G. Clinical efficacy of echinocandin antifungals. Curr. Opin. Infect. Dis. 14:2001;685-691.
43. Groll A.H., Walsh T.J. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs. 10:2001;1545-1558.
44. Hughes T.R., Marton M.J., Jones A.R., Roberts C.J., Stoughton R., Armour C.D., Bennett H.A., Coffey E., Dai H., He Y.D., Kidd M.J., King A.M., Meyer M.R., Slade D., Lum P.Y., Stepaniants S.B., Shoemaker D.D., Gachotte D., Chakraburtty K., Simon J., Bard M., Friend S.H. Functional discovery via a compendium of expression profiles. Cell. 102:2000;109-126.
45. De Backer M.D., Nelissen B., Logghe M., Viaene J., Loonen I., Vandoninck S., de Hoogt R., Dewaele S., Simons F.A., Verhasselt P., Vanhoof G., Contreras R., Luyten W.H. An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans. Nat. Biotechnol. 19:2001;235-241.
46. Folkman J. Proceedings: tumor angiogenesis factor. Adv. Cancer Res. 19:1974;331-358.
47. Abe J., Zhou W., Takuwa N., Taguchi J., Kurokawa K., Kumeda M., Takuwa Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res. 54:1994;3407-3412.
48. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 348:1990;555-557.
49. Sin N., Meng L., Wang M.Q., Wen J.J., Bornmann W.G., Crews C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. U. S. A. 94:1997;6099-6103.
50. Ketznelson H., Jamieson C.A. Science. 115:1952;70-71.
51. Gray N.S., Wodicka L., Thunnissen A.M., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., Kim S.H., Lockhart D.J., Schultz P.G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
52. Lockhart D.J., Wodicka L., Ho M.H. Affimetrix. 2001;. US20010055771.
53. Hunter T., Plowman G.D. The protein kinases of budding yeast: six score and more. Trends Biochem. Sci. 22:1997;18-22.
54. Lengeler K.B., Davidson R.C., D'Souza C., Harashima T., Shen W.C., Wang P., Pan X., Waugh M., Heitman J. Signal transduction cascades regulating fungal development and virulence. Microbiol. Mol. Biol. Rev. 64:2000;746-785.
55. Bachewich C., Thomas D.Y., Whiteway M. Depletion of a polo-like kinase in Candida albicans activates cyclase-dependent hyphal-like growth. Mol. Biol. Cell. 14:2003;2163-2180.
56. Morgan B.A., Bouquin N., Johnston L.H. Two component signal transduction systems in budding yeast MAP a different pathway? Trends Cell Biol. 5:1995;453-457.
57. Fabret C., Hoch J.A. A two-component signal transduction system essential for growth of Bacillus subtilis: implications for anti-infective therapy. J. Bacteriol. 180:1998;6375-6383.
58. Barrett J.F., Goldschmidt R.M., Lawrence L.E., Foleno B., Chen R., Demers J.P., Johnson S., Kanojia R., Fernandez J., Bernstein J., Licata L., Donetz A., Huang S., Hlasta D.J., Macielag M.J., Ohemeng K., Frechette R., Frosco M.B., Klaubert D.H., Whiteley J.M., Wang L., Hoch J.A. Antibacterial agents that inhibit two-component signal transduction systems. Proc. Natl. Acad. Sci. U. S. A. 95:1998;5317-5322.
59. Alex L.A., Borkovich K.A., Simon M.I. Hyphal development in Neurospora crassa: involvement of a two-component histidine kinase. Proc. Natl. Acad. Sci. U. S. A. 93:1996;3416-3421.
60. Nagahashi S., Mio T., Ono N., Yamada-Okabe T., Arisawa M., Bussey H., Yamada-Okabe H. Isolation of CaSLN1 and CaNIK1, the genes for osmosensing histidine kinase homologues, from the pathogenic fungus Candida albicans. Microbiology. 144:1998;425-432.
61. Srikantha T., Tsai L., Daniels K., Enger L., Highley K., Soll D.R. The two-component hybrid kinase regulator CaNIK1 of Candida albicans. Microbiology. 144:1998;2715-2729.
62. Deschenes R.J., Lin H., Ault A.D., Fassler J.S. Antifungal properties and target evaluation of three putative bacterial histidine kinase inhibitors. Antimicrob. Agents Chemother. 43:1999;1700-1703.
63. Hartwell L.H., Culotti J., Reid B. Genetic control of the cell-division cycle in yeast. I. Detection of mutants. Proc. Natl. Acad. Sci. U. S. A. 66:1970;352-359.
64. Nurse P., Thuriaux P., Nasmyth K. Genetic control of the cell division cycle in the fission yeast Schizosaccharomyces pombe. Mol. Gen. Genet. 146:1976;167-178.
65. Nurse P. Felix Hoppe-Seyler Lecture 1999. Cyclin dependent kinases and regulation of the fission yeast cell cycle. Biol. Chem. 380:1999;729-733.
66. Nasmyth K. A prize for proliferation. Cell. 107:2001;689-701.
67. Lew D.J., Weinert T., Pringle J.R. Cell cycle control in Saccharomyces cerevisiae. Pringle J.R., Broach J.R., Jones E.W. The Molecular and Cellular Biology of the Yeast Saccharomyces. Cell Cycle and Cell Biology. vol. 3:1997;607-695 Cold Spring Harbor Laboratory Press, Woodbury, NY.
68. Glow N.A.R. Cell biology and the cell cycle of Candida. Calderone R.A. Candida and Candidiasis. 2002;145-158 ASM Press, Washington, DC.
69. Brown A.J.P. Morphogenetic signalling pathways in Candida albicans. Calderone R.A. Candida and Candidiasis. 2002;95-106 ASM Press, Washington, DC.
70. Hazan I., Sepulveda-Becerra M., Liu H. Hyphal elongation is regulated independently of cell cycle in Candida albicans. Mol. Biol. Cell. 13:2002;134-145.
71. Mendenhall M.D., Hodge A.E. Regulation of Cdc28 Cyclin-Dependent protein kinase activity during the cell cycle of the yeast Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 62:1998;1191-1243.
72. Damagnez V., Cottarel G. Candida albicans Cdk1 and CYB1: cDNA homologues of the cdc2/CDC28 and cdc13/CLB1/CLB2 cell cycle control genes. Gene. 172:1996;137-141.
73. Sherlock G., Bahman A.M., Mahal A., Shieh J.C., Ferreira M., Rosamond J. Molecular cloning and analysis of CDC28 and cyclin homologues from the human fungal pathogen Candida albicans. Mol. Gen. Genet. 245:1994;716-723.
74. Morgan D.O. Principles of CDK regulation. Nature. 374:1995;131-134.
75. Meyerson M., Enders G.H., Wu C.L., Su L.K., Gorka C., Nelson C., Harlow E., Tsai L.H. A family of human cdc2-related protein kinases. EMBO J. 11:1992;2017-2909.
76. Di Lallo G., Gargano G., Maresca B. The Histoplasma capsulatum cdc2 gene is transcriptionally regulated during the morphologic transition. Gene. 140:1994;51-57.
77. Kobayashi H., Stewart E., Poon R., Adamczewski J.P., Gannon J., Hunt T. Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdk2 protein kinase subunits. Mol. Biol. Cell. 3:1992;1279-1294.
78. Whiteway M., Dignard D., Thomas D.Y. Dominant negative selection of heterologous genes: isolation of Candida albicans genes that interfere with Saccharomyces cerevisiae mating factor-induced cell cycle arrest. Proc. Natl. Acad. Sci. U. S. A. 89:1992;9410-9414.
79. Loeb J.D.J., Sepulveda-Becerra M., Hazan I., Liu H. A G1 cyclin is necessary for maintenance of filamentous growth in Candida albicans. Mol. Cell. Biol. 19:1999;4019-4027.
80. Russo A.A., Jeffrey P.D., Pavletich N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 3:1996;696-700.
81. Devault A., Martinez A.M., Fesquet D., Labbe J.C., Morin N., Tassan J.P., Nigg E.A., Cavadore J.C., Doree M. MAT1 ('menage a trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK. EMBO J. 14:1995;5027-5036.
82. Fesquet D., Labbe J.-C., Derancourt J., Capony J.-P., Galas S., Girard F., Lorca T., Shuttleworth J., Dorée M., Cavadore J.-C. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J. 12:1993;3111-3121.
83. Makela T.P., Tassan J.-P., Nigg E.A., Frutiger S., Hughes G.J., Weinberg R.A. A cyclin associated with the CDK-activating kinase MO15. Nature. 371:1994;254-257.
84. Harper J.W., Elledge S.J. The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev. 12:1998;285-289.
85. Roy R., Adamczeski J.P., Seroz T., Vermeulen W., Tassan J.-P., Schaeffer L., Nigg E.A., Hoeijmakers J.H.J., Egly J.-M. The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor. Cell. 79:1994;1093-1101.
86. Feaver W.J., Svejstrup J.Q., Henry N.L., Kornberg R.D. Relationship of CDK-activating kinase and RNA polymerase II CTD kinase TFIIH/TFIIK. Cell. 79:1994;1103-1109.
87. Kaldis P. The cdk-activating kinase (CAK): from yeast to mammals. Cell. Mol. Life Sci. 55:1999;284-296.
88. Hermand D., Pihlak A., Westerling T., Damagnez V., Vandenhaute J., Cottarel G., Makela T.P. Fission yeast Csk1 is a CAK-activating kinase (CAKAK). EMBO J. 17:1998;7230-7238.
89. Hermand D., Westerling T., Pihlak A., Thuret J.Y., Vallenius T., Tiainen M., Vandenhaute J., Cottarel G., Mann C., Makela T.P. Specificity of CDK activation in vivo by the two Caks Mcs6 and Csk1 in fission yeast. EMBO J. 20:2001;82-90.
90. Buck V., Russell P., Millar J.B. Identification of a cdk-activating kinase in fission yeast. EMBO J. 14:1995;6173-6183.
91. Faye G., Simon M., Valay J.G., Fesquet D., Facca C. Rig2, a RING finger protein that interacts with the Kin28/Ccl1 CTD kinase in yeast. Mol. Gen. Genet. 255:1997;460-466.
92. Valay J.G., Simon M., Dubois M.F., Bensaude O., Facca C., Faye G. The KIN28 gene is required both for RNA polymerase II mediated transcription and phosphorylation of the Rpb1p CTD. J. Mol. Biol. 249:1995;535-544.
93. Thuret J.Y., Valay J.G., Faye G., Mann C. Civ1 (CAK in vivo), a novel CDK-activating kinase. Cell. 86:1996;565-576.
94. Kaldis P., Sutton A., Solomon M.J. The CDK-activating kinase (CAK) from budding yeast. Cell. 86:1996;553-564.
95. Espinoza F.H., Farrell A., Erdjument-Bromage H., Tempst P., Morgan D.O. A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science. 273:1996;1714-1717.
96. Espinoza F.H., Farrell A., Nourse J.L., Chamberlin H.M., Gileadi O., Morgan D.O. Cak1 is required for Kin28 phosphorylation and activation in vivo. Mol. Cell. Biol. 18:1998;6365-6373.
97. Cross F.R., Levine K. Molecular evolution allows bypass of the requirement for activation loop phosphorylation of the Cdc28 cyclin-dependent kinase. Mol. Cell. Biol. 18:1998;2923-2931.
98. J.Y. Thuret, J.G. Valay, G. Faye, C. Mann, Commisariat à l'Energie Atomique (1999) WO9907836.
99. Tsakraklides V., Solomon M.J. Comparison of Cak1p-like cyclin-dependent kinase-activating kinases. J. Biol. Chem. 277:2002;33482-33489.
100. Manning G., Plowman G.D., Hunter T., Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem. Sci. 27:2002;514-520.
101. Schultz C., Link A., Leost M., Zaharevitz D.W., Gussio R., Sausville E.A., Meijer L., Kunick C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of Cdk1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 42:1999;2909-2919.
102. Hoessel R., Leclerc C., Endicott J.A., Nobel M.E.M., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederbeger E., Tang W., Eisenbrand G., Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1:1999;60-67.
103. Meijer L., Thunnissen A.M., White A.W., Garnier M., Nikolic M., Tsai H., Walter J., Cleverley K.E., Salinas P.C., Wu Y.Z., Biernat J., Mandelkow E.M., Kim S.H., Pettit G.R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7:2000;51-63.
104. Vesely J., Havlicek L., Strnad M., Blow J., Donella-Deana A., Pinna L., Letham D.S., Kato J.-Y., Detivaud L., Leclerc L., Meijer L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224:1994;771-786.
105. Meijer L., Borgne A., Mulner O., Chong J.P.J., Inagaki N., Inagaki M., Delcros J.-G., Moulinoux J.-P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536.
106. J.-L. Haesslein, Aventis Pharma (2000) WO200071543.
107. Shum P.W., Peet N.P., Weintraub P.M., Le T.B., Zhao Z., Barbone F., Cashman B., Tsay J., Dwyer S., Los P.C., Powers E.A., Kropp K., Wright P.S., Bitonti A.J., Dumont J., Borcherding D.R. The design and synthesis of purine inhibitors of Cdk2. III. Nucleosides Nucleotides Nucleic Acids. 20:2001;1067-1078.
108. Furet P., Zimmermann J., Capraro H.-G., Meyer T., Imbach P. Structure-based design of potent Cdk1 inhibitors derived from olomoucine. J. Comput.-Aided Mol. Des. 14:2000;403-409.
109. Dreyer M.K., Borcherding D.R., Dumont J.A., Peet N.P., Tsay J.T., Wright P.S., Bitonti A.J., Shen J., Kim S. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 44:2001;524-530.
110. Chang Y.-T., Gray N.S., Rosania G.R., Sutherlin D.P., Kwon S., Norman T.C., Sarohia R., Leost M., Meijer L., Schultz P.G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 6:1999;361-375.
111. Ledford B., Moody C.S., Mullican M., Namchuk M. Vertex Pharmaceuticals. 2002;. (WO02098876).
112. K.K. Murthi, A.F. Kluge, GPC Biotech, Inc. (2002) WO03004489.
113. F. Bordon-Pallier, J.L. Haesslein, Aventis Pharma (2000) WO02051843.